Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study
Latest Information Update: 17 Feb 2023
At a glance
- Drugs Docetaxel (Primary) ; Pembrolizumab (Primary)
- Indications Salivary gland cancer; Thyroid cancer
- Focus Therapeutic Use
- Acronyms The iPRIME Study
- 12 Nov 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Sep 2022.
- 19 Jul 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Sep 2021.
- 11 Sep 2020 Planned End Date changed from 1 Sep 2020 to 1 Sep 2022.